Paul Moorehead/LinkedIn
Aug 6, 2025, 10:47
Conquering Factor VIII Inhibitors: New Insights Into the ‘Devil’ of Hemophilia A Treatment Resistance
Flora Peyvandi posted on X:
”Exorcizing the devil of factor VIII inhibitors”
“For the Devil is a gentleman, and doesn’t keep his word” – G.K. Chesterton
In this issue of Blood Advances, Butera et al shed some light on the mystery of factor VIII (FVIII) inhibitors, the most diabolical complication of FVIII replacement therapy in patients with hemophilia A. Their work examined the impact of disulfide bonds on the antigenicity of the FVIII molecule, with possible implications for the understanding of immune responses to exogenous FVIII and for drug design.
Read the full article here.
Auothor: Paul C. Moorehead
Stay updated with Hemostasis Today.
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies
-
May 26, 2026, 15:22Shazmah Shaikh: One Visual Guide to Understand All Major Anticoagulants
-
May 26, 2026, 14:39Chidinma Favour։ Welcome to Day 25 of My 31-Day Stroke Awareness Series
-
May 26, 2026, 14:35Novel Insights Into Congenital and Acquired Coagulopathies – ICHCC
-
May 26, 2026, 14:24Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
-
May 26, 2026, 14:23Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?